RIBOLUTION Biomarker Center

We offer research and contract work in the field of molecular diagnostic analytics and their bioinformatic analysis, with a focus on personalized medicine. This includes the optimization and development of modern processes and applications for molecular diagnostics including next-generation sequencing.

Biomarker development and patient-focused complementary diagnostics

We are your partner for:

  • the development of algorithms and classification models for in vitro diagnostics.
  • gaining detailed insights into the mechanisms of action and resistance of novel drugs, such as gene and cell therapies, by using single cell analytics.
  • the accompanying evaluation of treatment results for clinical trials using omics-wide and multimodal measurements.
  • the implementation of the resulting biomarker signature as a software prototype for medical devices (for example as software for in vitro diagnostics).

Our offer for preclinical and clinical applications

Classical NGS methods:

  • Whole transcriptome sequencing (mRNA, totalRNA): gene expression profiling for biological and/or medical questions (for example, cancers, rare syndromes) as well as translational research
  • Amplicon-based sequencing: sequencing of selected genomic regions for precision oncology as well as testing for hereditary diseases
  • Genome sequencing / exome sequencing: genome profiling for cancer studies as well as translational research
  • Small genome sequencing: targeted or complete sequencing of genomes with low complexity (such as bacteria, viruses or phages)

Advanced NGS methods

  • Single cell sequencing and multiomics: transcriptome profiling and parallel detection of surface proteins of single cells. For example, for functional control of therapeutic CARs (e.g. CAR-T cells, CAR-NK cells) and for monitoring the success of therapy in patients.
  • Spatial sequencing (spatial transciptomics): Spatially resolved gene expression profiles in tissues close to single cell resolution, for example for parallel molecular and imaging characterization of tumor, tumor infiltrating immune cells and tumor microenvironment.

Medical Bioinformatics

  • Machine Learning & Multi-Omics: machine learning and AI for Deep Molecular Data; multimodal data analysis; statistical learning; integrative bioinformatics; pipeline development; power analysis.
  • Software Components for IVDs: Development of algorithms and software components for medical devices especially in vitro diagnostics (IVDs) and lab developed tests (LDTs - Lab Developed Tests).

Quality Assurance

  • ISO 9001 certified quality management system
  • NGS and bioinformatics according to established SOPs
  • Software development for medical devices and in vitro diagnostics according to IEC 62304, ISO 14971
  • DSGVO compliant data processing

Technical equipment

  • NextSeq 2000, Illumina
  • MiSeq, Illumina
  • MinION, Oxford Nanopore Technologies
  • 10x Chromium Controller
  • LUNA Automated Cell Counter
  • High Performance Computing Cluster
  • Other advanced technologies available


Kristin Reiche

Contact Press / Media

Dr. Kristin Reiche

Head of RIBOLUTION Biomarker Center, Head of Bioinformatics Unit

Fraunhofer Institute for Cell Therapy and Immunology
Perlickstraße 1
04103 Leipzig, Germany

Phone +49 341 35536-5223

Conny Blumert

Contact Press / Media

Dr. Conny Blumert

Head of Next-Generation Diagnostics Unit

Fraunhofer Institute for Cell Therapy and Immunology
Perlickstraße 1
04103 Leipzig, Germany

Phone +49 341 35536-3301

Scientific Advisor

Prof. Dr. Friedemann Horn

Our cooperation partners (selection)

  • Scads.AI
  • ecSeq
  • Leipzig University Hospital

Current project examples



New models for assessing pre-clinical safety of immunomodulatory therapies



Accelerate development and increase access of cancer patients to immunotherapy with engineered T cells



Saxony-wide field study on the spread of SARS-CoV-2 and accompanying research study


Fraunhofer CIMD

Early diagnosis of subclinical arthritis



Improving diagnosis and treatment in prostate cancer through Big Data analytics



Development of a novel classifier for the prognosis of aggressive disease progression in prostate carcinoma in needle biopsies